XML 24 R21.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2016
Dec. 31, 2018
Cash equivalents, at carrying value      
Payments to acquire marketable securities     $ 2,369,839    
Proceeds from sale of marketable securities     250,000 3,170,000    
Marketable securities, gross realized (gain) loss 4,435 1,568    
Marketable securities, gross unrealized gain (loss)     0      
Marketable securities       $ 250,388
Derivative, gain (loss) on derivative, net $ 65,207 $ (474) $ 341,107 $ 17,748    
Measurement Input, Expected Dividend Rate [Member]            
Fair value measurements, input percentage     0.00%      
Private Placement [Member] | Series B Preferred Stock [Member]            
Class of warrant or right, issued         127,346  
Private Placement [Member] | Placement Agent Warrants [Member] | Series B Preferred Stock [Member]            
Class of warrant or right, issued     127,346      
Private Placement [Member] | Debt Settlement [Member] | Series B Preferred Stock [Member] | Strategic Bio Partners [Member]            
Class of warrant or right, issued     295,945      
Equipment [Member]            
Property, plant and equipment, useful life     3 years